Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2019 Results Presentation and Webcast

Fecha : 21/02/2020 @ 10:07
Fuente : PR Newswire (US)
Emisora : Nordic Nanovector Asa (0R6Y)
Cotización : 14.56  0.0 (0.00%) @ 01:51
Nordic Nanovector Asa Cotización de acciones Gráfica

Nordic Nanovector ASA: Invitation to Fourth Quarter and Full Year 2019 Results Presentation and Webcast

Nordic Nanovector Asa (LSE:0R6Y)
Gráfica de Acción Histórica

2 meses : De Feb 2020 a Abr 2020

Haga Click aquí para más Gráficas Nordic Nanovector Asa.

OSLO, Norway, Feb. 21, 2020 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its results for the fourth quarter and full year 2019 on Thursday, 27 February 2020. A presentation by Nordic Nanovector's senior management team will take place at 8:30am CET at:

Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo

Meeting Room: VIPPETANGEN

The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media

The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Interim Reports/2019 from 7:00am CET the same day.

For further information, please contact:

IR enquiries
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com 

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.

CONTACT:

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa--invitation-to-fourth-quarter-and-full-year-2019-results-presentation-and-webc,c3041894

Copyright 2020 PR Newswire

Su Consulta Reciente
BMV
FIBRAPL14
Fibra Prol..
BMV
AMXL
América Mó..
BMV
ME
IPC México
BMV
ALSEA*
Alsea
FX
USDMXN
United Sta..
Las acciones que ha visto aparecerán en este recuadro, lo que le permite volver fácilmente a las cotizaciones que ha consultado previamente
Registrarse ahora para crear su lista personalizada de acciones en streaming.

Cotizaciones PLUS están en tiempo real. Cotizaciones NYSE y AMEX están con retraso de por lo menos 20 minutos.
El resto de las cotizaciones están con retraso de por lo menos 15 minutos al menos que se indique lo contrario.

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

P: V:mx D:20200409 12:03:29